Armata appoints David House as SVP, Finance and principal financial officer

Armata Pharmaceuticals, Inc.

David House appointed SVP, Finance and principal financial officer, effective Aug. 16, 2024.
Base salary $350,000; target bonus 40% of base; option for 75,000 shares vesting over 4 years.
Previously Corporate Controller and VP of Accounting at ZO Skin Health (acquired by Blackstone).
Prior principal financial officer Richard Rychlik will remain as Corporate Controller.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David House

Senior Vice President, Finance

ARMP · Armata Pharmaceuticals, Inc.

Effective: 2024-08-16
Filed: August 15, 2024, 7:59 PM ET

On July 31, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) entered into an employment letter agreement (the “ Agreement ”) with David House, pursuant to which he has agreed to serve as the Company’s Senior Vice President, Finance, effective August 16, 2024 (the “ Effective Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David House was appointed as Senior Vice President, Finance at Armata Pharmaceuticals, Inc..

Action: appointed
Role: Senior Vice President, Finance

Exact text from the filing

On July 31, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) entered into an employment letter agreement (the “ Agreement ”) with David House, pursuant to which he has agreed to serve as the Company’s Senior Vice President, Finance, effective August 16, 2024 (the “ Effective Date ”).

View on SEC.gov

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-090153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.